keyword
MENU ▼
Read by QxMD icon Read
search

Adjuvant sunitinib

keyword
https://www.readbyqxmd.com/read/29662544/sunitinib-in-the-treatment-of-renal-cell-carcinoma-an-update-on-recent-evidence
#1
REVIEW
Mimma Rizzo, Camillo Porta
Sunitinib is a multitarget tyrosine kinase inhibitor endowed mainly by antiangiogenic effects, although an indirect inhibitory effect on tumor growth and, more recently, a complex activity on antitumor immune response has been described. From approval by the US Food and Drug Administration (FDA) in January 2006, sunitinib represents a key molecule in the treatment of metastatic renal cell carcinoma (mRCC) due to the peculiar molecular pathogenesis of this neoplasm. Over the past 10 years, clinical trials and real-world experiences helped clinicians to understand how, when and for how long to use sunitinib...
August 2017: Therapeutic Advances in Urology
https://www.readbyqxmd.com/read/29589470/the-merit-of-tyrosine-kinase-inhibitors-in-the-adjuvant-setting-of-high-risk-renal-cell-carcinoma-a-meta-analysis
#2
Hampig Raphael Kourie, Ziad Bakouny, Roland Eid, Fady Gh Haddad, Joseph Kattan
AIM: As no meta-analyses have evaluated tyrosine kinase inhibitors in the adjuvant setting of high-risk renal cell carcinoma (RCC), the aim was to evaluate the benefit of sunitinib and pazopanib in the adjuvant setting. METHODS: This meta-analysis included all Phase III randomized controlled trials evaluating adjuvant sunitinib and pazopanib in high-risk RCC. Primary outcome was the comparison of disease-free survival (DFS) between tyrosine kinase inhibitors and placebo...
March 28, 2018: Future Oncology
https://www.readbyqxmd.com/read/29573266/sorafenib-paradoxically-activates-the-ras-raf-erk-pathway-in-polyclonal-human-nk-cells-during-expansion-and-thereby-enhances-effector-functions-in-a-dose-and-time-dependent-manner
#3
Julian Lohmeyer, Thomas Nerreter, Julia Dotterweich, Hermann Einsele, Ruth Seggewiss-Bernhardt
Natural killer (NK) cells play a major role in host immunity against leukemia and lymphoma. However, clinical trials applying NK cells have not been as efficient as hoped for. Patients treated with RAF inhibitors exhibit increased tumor infiltration by immune cells suggesting that a combination of RAF inhibitors with immunotherapy might be beneficial. As MAPKs such as CRAF regulate NK cell functions, we performed an in vitro investigation on the potential of clinically relevant short acting tyrosine kinase inhibitors (TKIs) as potential adjuvants for NK cell therapy: NK cells from healthy human blood donors were thus treated with sorafenib, sunitinib or the pan-RAF inhibitor ZM336372 during ex vivo expansion...
March 24, 2018: Clinical and Experimental Immunology
https://www.readbyqxmd.com/read/29522146/the-us-food-and-drug-administration-s-approval-of-adjuvant-sunitinib-for-renal-cell-cancer-a-case-of-regulatory-capture
#4
Bishal Gyawali, Daniel A Goldstein
No abstract text is available yet for this article.
March 8, 2018: JAMA Oncology
https://www.readbyqxmd.com/read/29507530/the-tyrosine-kinase-inhibitor-nilotinib-is-more-efficient-than-mitotane-in-decreasing-cell-viability-in-spheroids-prepared-from-adrenocortical-carcinoma-cells
#5
Elaine Silveira, Isadora Pontes Cavalcante, Jean Lucas Kremer, Pedro Omori Ribeiro de Mendonça, Claudimara Ferini Pacicco Lotfi
Background: New drugs for adrenocortical carcinoma (ACC) are needed because most patients undergo rapid disease progression despite surgery and adjuvant therapy with mitotane. In this study, we aimed to investigate the in vitro effects of different chemotherapy drugs, alone or combined with mitotane, on the viability of adrenocortical carcinoma cells. Methods: Everolimus, sunitinib, zoledronic acid, imatinib and nilotinib cytotoxicity, alone or combined with mitotane were tested on ACC H295R cells in monolayer or spheroid cultures using MTS assays and confocal microscopy...
2018: Cancer Cell International
https://www.readbyqxmd.com/read/29449091/adjuvant-therapies-in-nonmetastatic-renal-cell-carcinoma-a-review-of-the-literature
#6
REVIEW
Marco Bandini, Ariane Smith, Michele Marchioni, Raisa S Pompe, Tristan F Martel, Luca Cindolo, Francesco Montorsi, Shahrokh F Shariat, Alberto Briganti, Anil Kapoor, Umberto Capitanio, Pierre I Karakiewicz
To conduct a review of literature on adjuvant therapy in nonmetastatic renal-cell carcinoma (nmRCC) treated with nephrectomy and to describe the efficacy of adjuvant agents on cancer control outcomes. A review of the literature was performed in January 2018 to identify all studies evaluating adjuvant therapy in patients with nmRCC treated with nephrectomy using PubMed, Embase, Medline, and Cochrane Library databases. The following keywords were used: adjuvant therapy, renal-cell carcinoma, nonmetastatic, targeted molecular therapy, kidney cancer...
February 2, 2018: Clinical Genitourinary Cancer
https://www.readbyqxmd.com/read/29435133/elucidating-mechanisms-of-sunitinib-resistance-in-renal-cancer-an-integrated-pathological-molecular-analysis
#7
Henriett Butz, Qiang Ding, Roy Nofech-Mozes, Zsuzsanna Lichner, Heyu Ni, George M Yousef
Upon sunitinib treatment of metastatic renal cell carcinoma patients eventually acquire resistance. Our aim was to investigate microRNAs behind sunitinib resistance. We developed an in vivo xenograft and an in vitro model and compared morphological, immunhistochemical, transcriptomical and miRNome data changes during sunitinib response and resistance by performing next-generation mRNA and miRNA sequencing. Complex bioinformatics (pathway, BioFunction and network) analysis were performed. Results were validated by in vitro functional assays...
January 12, 2018: Oncotarget
https://www.readbyqxmd.com/read/29435010/chloroquine-potentiates-the-anticancer-effect-of-sunitinib-on-renal-cell-carcinoma-by-inhibiting-autophagy-and-inducing-apoptosis
#8
Man-Li Li, You-Zhi Xu, Wen-Jie Lu, Yong-Huai Li, Shi-Sheng Tan, Hong-Jun Lin, Tian-Ming Wu, Yan Li, Si-Ying Wang, Ying-Lan Zhao
Sunitinib based adjuvant chemotherapy combined with chloroquine (CQ) for the treatment of renal cell carcinoma (RCC) is in clinical trials; however, its anti-RCC effect and the mechanism remain unclear. In the present study, the anti-RCC effect of sunitinib with CQ and the underlying mechanism was investigated. An MTT assay demonstrated that CQ enhanced the proliferation inhibitory effect of sunitinib against the OS-RC-2 RCC cell line. CQ inhibited sunitinib-induced autophagy in OS-RC-2, which was evidenced by the inhibition of autophagic vacuoles, acidic vesicular organelle formation, light chain 3 (LC3)-II recruitment to the autophagosomes and the conversion of LC3-I to LC3-II, as induced by sunitinib...
March 2018: Oncology Letters
https://www.readbyqxmd.com/read/29433972/re-adjuvant-sunitinib-in-high-risk-renal-cell-carcinoma-after-nephrectomy
#9
Amirali Salmasi, Izak Faiena, Alexandra Drakaki, Allan J Pantuck
No abstract text is available yet for this article.
February 9, 2018: European Urology
https://www.readbyqxmd.com/read/29409504/unusual-progression-of-renal-cell-carcinoma-with-carcinomatosis-peritoneii-and-krukenberg-tumour-and-alopecia-with-sunitinib-therapy-in-young-female
#10
Manoj Pandey, Mahendran Ramasamy, Mridula Shukla
BACKGROUND: Sunitinib is a multiple receptor tyrosine kinase inhibitor (TKI) used for the treatment of renal cell carcinoma (RCC). It increases the median survival considerably with minimum side effects. Alopecia is one of the rare side effects. Metastasis to the ovary is also rare. We report a case of RCC metastasizing to the ovary developing alopecia early on starting sunitinib. CASE PRESENTATION: A 22-year-old hypothyroid girl underwent right radical nephrectomy for T2N0 RCC...
February 6, 2018: World Journal of Surgical Oncology
https://www.readbyqxmd.com/read/29374054/immune-biomarkers-predictive-for-disease-free-survival-with-adjuvant-sunitinib-in-high-risk-locoregional-renal-cell-carcinoma-from-randomized-phase-iii-s-trac-study
#11
Daniel J George, Jean-François Martini, Michael Staehler, Robert J Motzer, Ahmed Magheli, Bernard Escudier, Paola Gerletti, Sherry Li, Michelle Casey, Brigitte Laguerre, Hardev S Pandha, Allan J Pantuck, Anup Patel, Maria J Lechuga, Alain Ravaud
Purpose: Adjuvant sunitinib therapy compared with placebo prolonged disease-free survival (DFS) in patients with locoregional high-risk renal cell carcinoma (RCC) in the S-TRAC trial (ClinicalTrials.gov number NCT00375674). A prospectively designed exploratory analysis of tissue biomarkers was conducted to identify predictors of treatment benefit. Experimental Design: Tissue blocks were used for immunohistochemistry (IHC) staining of programmed cell death ligand 1 (PD-L1), CD4, CD8, and CD68. DFS was compared between < versus ≥ median IHC parameter using the Kaplan-Meier method...
January 26, 2018: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/29274030/fatigue-among-patients-with-renal-cell-carcinoma-receiving-adjuvant-sunitinib-or-sorafenib-patient-reported-outcomes-of-ecog-acrin-e2805-trial
#12
Fengmin Zhao, David Cella, Judith Manola, Robert S DiPaola, Lynne I Wagner, Naomi S B Haas
BACKGROUND: E2805 was a phase III trial to test whether adjuvant sunitinib or sorafenib could improve disease-free survival compared to placebo in patients with renal cell carcinoma. Patient-reported outcomes (PRO), focusing on fatigue, were evaluated as a secondary endpoint. PATIENTS AND METHODS: A total of 463 patients participated in the PRO study. Fatigue was measured by the FACIT Fatigue scale and PROMIS Fatigue SF1 measure at baseline, week 10, and week 22...
December 23, 2017: Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer
https://www.readbyqxmd.com/read/29220298/gastrointestinal-stromal-tumors
#13
Margaret von Mehren, Heikki Joensuu
GI stromal tumors (GISTs) are neoplasms with a varying malignancy potential ranging from virtually indolent tumors to rapidly progressing cancers. GISTs occur throughout the intestinal tract, and most harbor an activating mutation in either KIT or platelet-derived growth factor A ( PDGFRA). Diagnosis is made using immunohistochemistry, but molecular testing with mutation analysis is paramount for selection of appropriate therapy. Most small GISTs are cured with surgery. Tyrosine kinase inhibitor (TKI) therapy has led to substantial improvements in survival, both for patients with localized GIST and those with advanced disease...
January 10, 2018: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/29134564/seom-clinical-guideline-for-treatment-of-kidney-cancer-2017
#14
E Gallardo, M J Méndez-Vidal, J L Pérez-Gracia, J M Sepúlveda-Sánchez, M Campayo, I Chirivella-González, X García-Del-Muro, A González-Del-Alba, E Grande, C Suárez
The goal of this article is to provide recommendations about the management of kidney cancer. Based on pathologic and molecular features, several kidney cancer variants were described. Nephron-sparing techniques are the gold standard of localized disease. After a randomized trial, sunitinib could be considered in adjuvant treatment in high-risk patients. Patients with advanced disease constitute a heterogeneous population. Prognostic classification should be considered. Both sunitinib and pazopanib are the standard options for first-line systemic therapy in advanced renal cell carcinoma...
January 2018: Clinical & Translational Oncology
https://www.readbyqxmd.com/read/29066509/tumor-microvessel-density-as-a-prognostic-marker-in-high-risk-renal-cell-carcinoma-patients-treated-on-ecog-acrin-e2805
#15
Lucia B Jilaveanu, Maneka Puligandla, Sarah A Weiss, Xin Victoria Wang, Christopher Zito, Keith T Flaherty, Marta Boeke, Veronique Neumeister, Robert L Camp, Adebowale Adeniran, Michael Pins, Judith Manola, Robert S DiPaola, Naomi B Haas, Harriet M Kluger
Purpose: Increased vascularity is a hallmark of renal cell carcinoma (RCC). Microvessel density (MVD) is one measurement of tumor angiogenesis; however, its utility as a biomarker of outcome is unknown. ECOG-ACRIN 2805 (E2805) enrolled 1,943 resected high-risk RCC patients randomized to adjuvant sunitinib, sorafenib, or placebo. We aimed to determine the prognostic and predictive role of MVD in RCC. Experimental Design: We obtained pretreatment primary RCC nephrectomy tissues from 822 patients on E2805 and constructed tissue microarrays...
January 1, 2018: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/29035731/postoperative-adjuvant-sorafenib-or-sunitinib-for-nonmetastatic-renal-cell-carcinoma-with-venous-tumor-thrombus-a-prospective-cohort-study
#16
Liangyou Gu, Hongzhao Li, Luyao Chen, Xintao Li, Baojun Wang, Qingbo Huang, Fan Zhang, Yang Fan, Yu Gao, Cheng Peng, Xin Ma, Xu Zhang
PURPOSE: To evaluate the efficacy and safety of antiangiogenic agents (sorafenib and sunitinib) as postoperative adjuvant therapy in patients with nonmetastatic renal cell carcinoma (RCC) and venous tumor thrombus (VTT). MATERIAL AND METHODS: From March 2006 to January 2016, 147 patients who met the inclusion criteria were enrolled; 27 patients received sorafenib, and 17 patients received sunitinib. After radical nephrectomy and thrombectomy, the duration of maintenance targeted medication treatment was approximately 1 year...
December 2017: Translational Oncology
https://www.readbyqxmd.com/read/29032154/are-we-ready-for-adjuvant-sunitinib-in-high-risk-renal-cell-carcinoma
#17
EDITORIAL
Jozefina Casuscelli, James J Hsieh
No abstract text is available yet for this article.
January 2018: European Urology
https://www.readbyqxmd.com/read/28993730/molecular-guided-therapy-provides-sustained-clinical-response-in-refractory-choroid-plexus-carcinoma
#18
Albert Cornelius, Jessica Foley, Jeffrey Bond, Abhinav B Nagulapally, Julie Steinbrecher, William P D Hendricks, Maria Rich, Sangeeta Yendrembam, Genevieve Bergendahl, Jeffrey M Trent, Giselle S Sholler
Choroid plexus carcinomas (CPCs) are rare, aggressive pediatric brain tumors with no established curative therapy for relapsed disease, and poor survival rates. TP53 Mutation or dysfunction correlates with poor or no survival outcome in CPCs. Here, we report the case of a 4 month-old female who presented with disseminated CPC. After initial response to tumor resection and adjuvant-chemotherapy, the tumor recurred and metastasized with no response to aggressive relapse therapy suggesting genetic predisposition...
2017: Frontiers in Pharmacology
https://www.readbyqxmd.com/read/28967554/adjuvant-sunitinib-for-high-risk-renal-cell-carcinoma-after-nephrectomy-subgroup-analyses-and-updated-overall-survival-results
#19
Robert J Motzer, Alain Ravaud, Jean-Jacques Patard, Hardev S Pandha, Daniel J George, Anup Patel, Yen-Hwa Chang, Bernard Escudier, Frede Donskov, Ahmed Magheli, Giacomo Carteni, Brigitte Laguerre, Piotr Tomczak, Jan Breza, Paola Gerletti, Mariajose Lechuga, Xun Lin, Michelle Casey, Lucile Serfass, Allan J Pantuck, Michael Staehler
BACKGROUND: Adjuvant sunitinib significantly improved disease-free survival (DFS) versus placebo in patients with locoregional renal cell carcinoma (RCC) at high risk of recurrence after nephrectomy (hazard ratio [HR] 0.76, 95% confidence interval [CI] 0.59-0.98; p=0.03). OBJECTIVE: To report the relationship between baseline factors and DFS, pattern of recurrence, and updated overall survival (OS). DESIGN, SETTING, AND PARTICIPANTS: Data for 615 patients randomized to sunitinib (n=309) or placebo (n=306) in the S-TRAC trial...
January 2018: European Urology
https://www.readbyqxmd.com/read/28935400/adjuvant-sunitinib-in-high-risk-patients-with-uveal-melanoma-comparison-with-institutional-controls
#20
Matias E Valsecchi, Marlana Orloff, Rino Sato, Inna Chervoneva, Carol L Shields, Jerry A Shields, Michael J Mastrangelo, Takami Sato
PURPOSE: To compare overall survival in high-risk patients with primary uveal melanoma who received adjuvant sunitinib with institutional controls. DESIGN: Retrospective cohort. PARTICIPANTS: Selection criteria were (1) monosomy 3 and 8q amplification by cytogenetic or DecisionDx-UM Class 2 and (2) monosomy 3 and large tumor size (T3-4 by American Joint Committee on Cancer classification). Exclusion criteria were date of diagnosis before 2007 or after 2013 and age <18 years...
September 18, 2017: Ophthalmology
keyword
keyword
110017
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"